Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArriVent BioPharma

19.54
+1.407.72%
Volume:202.63K
Turnover:3.86M
Market Cap:664.68M
PE:-7.64
High:19.69
Open:17.86
Low:17.43
Close:18.14
Loading ...

Company Profile

Company Name:
ArriVent BioPharma
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
52
Office Location:
18 Campus Boulevard,Suite 100,Newtown Square,Pennsylvania,United States
Zip Code:
19073
Fax:
- -
Introduction:
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Directors

Name
Position
Zhengbin Yao
Chief Executive Officer and Chairman of Board
Stuart Lutzker
President of Research and Development and Director
Bahija Jallal
Director
Carl L. Gordon
Director
Chris W. Nolet
Director
James Healy
Director

Shareholders

Name
Position
Zhengbin Yao
Chief Executive Officer and Chairman of Board
Robin LaChapelle
Chief Operating Officer
Winston Kung
Chief Financial Officer and Treasurer
James Kastenmayer
General Counsel and Secretary
Stuart Lutzker
President of Research and Development and Director